BioLineRx (BLRX)
0.65
+0.01 (1.56%)
Upcoming Events
Latest Headlines
Form 6-K BioLineRx Ltd. For: Apr 17
April 17, 2024 7:12 AM - SEC Filing
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
April 17, 2024 7:00 AM - PR NewsWire
Form 6-K BioLineRx Ltd. For: Apr 10
April 10, 2024 7:25 AM - SEC Filing
BioLineRx (BLRX) Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
April 10, 2024 7:06 AM - StreetInsider
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
April 10, 2024 7:00 AM - PR NewsWire
Form 6-K BioLineRx Ltd. For: Apr 01
April 1, 2024 10:35 AM - SEC Filing
Form 424B5 BioLineRx Ltd.
April 1, 2024 10:31 AM - SEC Filing
BioLineRx (BLRX) Announces 7.5M Share Offering at $0.80/sh
April 1, 2024 9:01 AM - StreetInsider
BioLineRx Announces $6 Million Registered Direct Offering
April 1, 2024 9:00 AM - PR NewsWire
Form 20-F/A BioLineRx Ltd. For: Dec 31
March 26, 2024 4:58 PM - SEC Filing
Form 20-F BioLineRx Ltd. For: Dec 31
March 26, 2024 8:02 AM - SEC Filing
Form 6-K BioLineRx Ltd. For: Mar 26
March 26, 2024 7:06 AM - SEC Filing
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
March 26, 2024 7:00 AM - PR NewsWire
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
March 20, 2024 7:00 AM - PR NewsWire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
March 6, 2024 8:02 AM - StreetInsider
Form 6-K BioLineRx Ltd. For: Mar 04
March 4, 2024 7:47 AM - SEC Filing
BioLineRx (BLRX) Receives Patent for Method of Manufacturing Motixafortide
March 4, 2024 7:03 AM - StreetInsider
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
March 4, 2024 7:00 AM - PR NewsWire
Form 6-K BioLineRx Ltd. For: Feb 28
February 28, 2024 7:08 AM - SEC Filing
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
February 28, 2024 7:00 AM - PR NewsWire
Form 6-K BioLineRx Ltd. For: Feb 16
February 16, 2024 7:07 AM - SEC Filing
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetin
February 16, 2024 7:00 AM - PR NewsWire
Full Article List
